Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) saw an uptick in trading volume on Thursday . 6,190 shares traded hands during trading, an increase of 356% from the previous session’s volume of 1,357 shares.The stock last traded at $11.7657 and had previously closed at $12.35.
Oxford BioMedica Stock Performance
The company has a quick ratio of 1.67, a current ratio of 1.89 and a debt-to-equity ratio of 3.08. The stock’s 50 day moving average is $9.36 and its two-hundred day moving average is $8.02.
Oxford BioMedica Company Profile
Oxford BioMedica is a clinical-stage gene and cell therapy company headquartered in Oxford, United Kingdom. The company specializes in the development, manufacturing and commercialization of lentiviral vector delivery systems for use in treating serious diseases. Its proprietary LentiVector® platform underpins both in-house development programs and third-party collaborations, enabling the stable integration of therapeutic genes into target cells.
In its research pipeline, Oxford BioMedica is advancing candidates across ophthalmology, neuroscience and oncology indications.
Read More
- Five stocks we like better than Oxford BioMedica
- Do not delete, read immediately
- Refund From 1933: Trump’s Reset May Create Instant Wealth
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
